ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DICE DICE Therapeutics Inc

47.55
0.00 (0.00%)
31 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
DICE Therapeutics Inc NASDAQ:DICE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 47.55 49.96 47.99 0 01:00:00

Form 15-12G - Securities registration termination [Section 12(g)]

21/08/2023 1:00pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-40794

 

 

DICE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

400 East Jamie Court, Suite 300

South San Francisco, California 94080

Telephone: (650) 566-1420

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common stock, $0.0001 par value per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

 

Rule 12g-4(a)(2)

 

Rule 12h-3(b)(1)(i)

 

Rule 12h-3(b)(1)(ii)

 

Rule 15d-6

 

Rule 15d-22(b)

 

Approximate number of holders of record as of the certification or notice date: One holder

Pursuant to the requirements of the Securities Exchange Act of 1934, DICE Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: August 21, 2023     DICE Therapeutics, Inc.
    By:  

/s/ Philip L. Johnson

    Name:   Philip L. Johnson
    Title:   President

 

 

 

 


1 Year DICE Therapeutics Chart

1 Year DICE Therapeutics Chart

1 Month DICE Therapeutics Chart

1 Month DICE Therapeutics Chart

Your Recent History